Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors (2021)
- Authors:
- USP affiliated authors: CUNHA, FERNANDO DE QUEIROZ - FMRP ; WANDERLEY, CARLOS WAGNER DE SOUZA - FMRP
- Unidade: FMRP
- DOI: 10.1016/j.annonc.2021.08.1377
- Subjects: IMUNOLOGIA; METABOLISMO; GLICOSE
- Language: Inglês
- Imprenta:
- Source:
- Título: Annals of Oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 32, supl. S5, p. S846-S847, res. 993P, 2021
- Conference titles: European Society for Medical Oncology Congress - ESMO
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SILVA, S. B et al. Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors. Annals of Oncology. Amterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.annonc.2021.08.1377. Acesso em: 12 fev. 2026. , 2021 -
APA
Silva, S. B., Wanderley, C. W. de S., Marin, J. F. G., Macedo, M. P. de, Nascimento, E. .C. T. do, Antonacio, F. F., et al. (2021). Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors. Annals of Oncology. Amterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.annonc.2021.08.1377 -
NLM
Silva SB, Wanderley CW de S, Marin JFG, Macedo MP de, Nascimento E .CT do, Antonacio FF, Cunha F de Q, Castro Jr. G de. Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors [Internet]. Annals of Oncology. 2021 ; 32 S846-S847.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1016/j.annonc.2021.08.1377 -
Vancouver
Silva SB, Wanderley CW de S, Marin JFG, Macedo MP de, Nascimento E .CT do, Antonacio FF, Cunha F de Q, Castro Jr. G de. Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors [Internet]. Annals of Oncology. 2021 ; 32 S846-S847.[citado 2026 fev. 12 ] Available from: https://doi.org/10.1016/j.annonc.2021.08.1377 - Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications
- Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19
- Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19
- Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo
- Platelets fuel the inflammasome activation of innate immune cells
- Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors
- Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
- Paradoxical interaction between cancer and long-term postsepsis disorder: impairment of de novo carcinogenesis versus favoring the growth of established tumors
- The role of neutrophils in neuro-immune modulation
- Adjunctive benefits of systemic etoricoxib in non-surgical treatment of aggressive periodontitis: short-term evaluation
Informações sobre o DOI: 10.1016/j.annonc.2021.08.1377 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003232368.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
